Article ; Online: Real-life experiences with goal-directed prohemostatic therapy with fibrinogen concentrate, prothrombin complex concentrate, and recombinant factor VIIa: a retrospective study of 287 consecutive patients.
Scandinavian journal of clinical and laboratory investigation
2022 Volume 82, Issue 2, Page(s) 156–161
Abstract: The Danish Capital Region Blood Bank operates a 24/7 on-call service staffed with physicians specialized in hemostatic management to guide clinicians in hemostatic resuscitation, including administration of prohemostatic therapy (PHT). The outcome of ... ...
| Abstract | The Danish Capital Region Blood Bank operates a 24/7 on-call service staffed with physicians specialized in hemostatic management to guide clinicians in hemostatic resuscitation, including administration of prohemostatic therapy (PHT). The outcome of patients who receive PHT as part of hemostatic resuscitation remains unanswered. The objective of this study was therefore to investigate clinical outcome of patients receiving PHT managed by the on-call service. We identified 287 patients who received PHT during 2015-16, of which 161 (59%) received fibrinogen concentrate (FC), 111 (39%) received prothrombin complex concentrate (PCC), and 15 (5%) received recombinant factor VIIa (rFVIIa) as the first product. Patients were critically ill with a 30-day mortality of 31%. Among FC recipients, cardiothoracic admission, non-trauma, and antithrombotics predicted survival. FC recipients had lower platelet count and thrombelastography clot strengths than the other PHT groups and within the group, these factors predicted mortality. The symptomatic thromboembolic event (TE) rate at 30 days was 5%. For PCC recipients, vitamin K antagonists predicted survival, while rivaroxaban predicted mortality. TE rate was 2%. We did not identify factors associated with survival in the small group of rFVIIa recipients. TE rate was 13%. In summary, trauma and coagulopathy predicted mortality in patients who received FC and our data suggest that optimization of PHT algorithms may be possible. Outcome of patients who received PCC was comparable to results reported elsewhere and its use may be safe in a setting as reported here. Recombinant FVIIa was rarely used but had the highest incidence of arterial thromboembolism. |
|---|---|
| MeSH term(s) | Blood Coagulation Factors/therapeutic use ; Factor VIIa ; Fibrinogen/analysis ; Fibrinogen/therapeutic use ; Goals ; Hemostatics/therapeutic use ; Humans ; Recombinant Proteins/adverse effects ; Retrospective Studies ; Thromboembolism/drug therapy |
| Chemical Substances | Blood Coagulation Factors ; Hemostatics ; Recombinant Proteins ; prothrombin complex concentrates (37224-63-8) ; Fibrinogen (9001-32-5) ; recombinant FVIIa (AC71R787OV) ; Factor VIIa (EC 3.4.21.21) |
| Language | English |
| Publishing date | 2022-02-17 |
| Publishing country | England |
| Document type | Journal Article |
| ZDB-ID | 3150-1 |
| ISSN | 1502-7686 ; 0036-5513 |
| ISSN (online) | 1502-7686 |
| ISSN | 0036-5513 |
| DOI | 10.1080/00365513.2022.2040048 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ud II Zs.150: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.